Abstract: ObjectiveTo investigate the correlation of RRM2 expression with angiogenesis in epithelian ovarian cancer. Methods The mRNA and protein level of RRM2 and CD105 in 98 ovarian specimens(including 15 normal,15 benign, 6 borderline and 62 malignant) were detected by RT-PCR and immunohistochemistry.The relationship between the expressions of two genes was analyzed. Results (1)The mRNA level and protein positive rates of RRM2 in borderline ovarian neoplasms(1.586±0.650, 66.67 %) and ovarian cancers(1.870±0.61, 69.35%)were both higher than those in normal group (0.771±0.495,0) and benign group(0.952±0.601, 26.67%) (P＜0.05).(2)The mRNA level and MVD of CD 105 in borderline ovarian neoplasms(2.190±0.512, 23.15±4.38) and ovarian cancers(2.735±0.636,25.27±6.91) were both higher than those in normal group(0.686±0.637,3.40±1.78) and benign group(0.763±0.547, 12.15±2.29)(P＜0.05).(3) The mRNA level and positive rates of RRM2 were higher in borderline ovarian neoplasms and clinical stage Ⅰ～Ⅱ than those in normal group and benign group (P＜0.05)，and higher in clinical stage Ⅲ～Ⅳ than that in stage Ⅰ～Ⅱ(t=-2.370, χ²=5.937，P＜0.05).(4)Expression of RRM2mRNA was positively correlated with CD105mRNA expression in ovarian cancer tissues(r=0.713,P＜0.05). Conclusion RRM2 might have participated the early stage of the origination and progression of epithelian ovarian cancer, and might have encouraged effects on angiogenesis of epithelial ovarian cancer, so it may be another new tumor marker for earlier diagnosis.